Identifying Efficacious Thresholds for Bleeding Risk Reduction in Relation to Factor IX (FIX) Levels in Hemophilia B Patients Receiving IDELVION

被引：0
|
作者：
Fosser, C. [1 ]
Roberts, J. [2 ]
Tortorici, M. [2 ]
Jacobs, I. [2 ]
Sidhu, J. [2 ]
机构：
[1] Cytel, Cambridge, MA USA
[2] CSL Behring, King Of Prussia, PA USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2017年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
M-010
引用
收藏
页码：S15 / S15
页数：1
相关论文
共 50 条
  • [41] Activated partial thromboplastin time-based clot waveform analysis enables measurement of very low levels of factor IX activity in patients with severe hemophilia B
    Nishiyama, Atsuko
    Ogiwara, Kenichi
    Mizumachi, Kuniyoshi
    Hashimoto, Naoki
    Takeyama, Masahiro
    Nogami, Keiji
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (05) : 778 - 786
  • [42] Reduction in Annualized Bleeding and Factor IX Consumption up to 2.5 Years in Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy
    Leebeek, Frank
    Meijer, K.
    Coppens, Michiel
    Kampmann, Peter
    Klamroth, Robert
    Schutgens, Roger
    Castaman, Giancarlo
    Seifried, Erhard
    Schwaeble, J.
    Bonig, Halvard
    Sawyer, Eileen K.
    Miesbach, W.
    BLOOD, 2018, 132
  • [43] IDEAL STUDY: A REAL-WORLD ASSESSMENT OF TREATMENT REGIMENS, FACTOR IX TROUGH LEVELS AND CONCENTRATE CONSUMPTION IN HAEMOPHILIA B PATIENTS RECEIVING ALBUTREPENONACOG ALFA IN ITALY
    Tagliaferri, A.
    Molinari, A. C.
    Peyvandi, F.
    Coppola, A.
    Finardi, A.
    Schiavetti, I.
    Rocino, A.
    Castaman, G.
    HAEMOPHILIA, 2022, 28 : 60 - 60
  • [44] REAL-WORLD SPECIALTY PHARMACY DISPENSATION AND EXPENDITURES ASSOCIATED WITH STANDARD AND EXTENDED HALF-LIFE RECOMBINANT FACTOR IX PRODUCTS AMONG HEMOPHILIA B PATIENTS RECEIVING ON-DEMAND REGIMENS
    Fogarty, Patrick F.
    Alvir, Jose
    Chhabra, Amit
    McDonald, Margaret
    Tortella, Bartholomew J.
    Pleil, Andreas M.
    Spurden, Dean
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (09) : E19 - E20
  • [45] SPK-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B at the Low Vector Dose Achieved Sustained, Continuous Factor IX Activity Levels Adequate for Endogenous Prophylaxis Preventing Bleeding Episodes and Reducing the Risk of Immune Response
    George, Lindsey A.
    Sullivan, Spencer K.
    Giermasz, Adam
    Ducore, Jonathan
    Rasko, John
    Teitel, Jerome
    McGuinn, Catherine
    Galvao, Aline
    Luk, Alvin Y.
    Galas, Teresa
    Wright, Fraser
    Chen, YiFeng
    Hui, Daniel J.
    Wachtel, Katie
    Takefman, Daniel
    Couto, Linda B.
    Carr, Marcus E.
    Anguela, Xavier M.
    High, Katherine A.
    MOLECULAR THERAPY, 2017, 25 (05) : 331 - 332
  • [46] Relationship between plasma tissue Factor Pathway Inhibitor (TFPI) levels, thrombin generation and clinical risk of bleeding in patients with severe haemophilia A or B
    Tardy-Poncet, Brigitte
    Montmartin, Aurelie
    Chambost, Herve
    Lienhart, Anne
    Frotscher, Birgit
    Morange, Pierre-Emmanuel
    Falaise, Celine
    Collange, Fanny
    Dargaud, Yesim
    Toussaint-Hacquard, Marie
    Ardillon, Laurent
    Wibaut, Benedicte
    Jeanpierre, Emmanuelle
    Nguyen, Philippe
    Volot, Fabienne
    Tardy, Bernard
    HAEMOPHILIA, 2024, 30 (03) : 693 - 701
  • [47] Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months' Follow-up
    Pipe, Steven W.
    Leebeek, Frank W. G.
    Recht, Michael
    Key, Nigel S.
    Lattimore, Susan
    Castaman, Giancarlo
    Coppens, Michiel
    Cooper, David
    Gut, Robert
    Slawka, Sergio
    Verweij, Stephanie
    Dolmetsch, Ricardo
    Li, Yanyan
    Monahan, Paul E.
    Miesbach, Wolfgang A.
    BLOOD, 2022, 140 : 4910 - 4912
  • [48] High plasma D-dimer and von Willebrand factor levels are associated with risk of upper gastrointestinal bleeding in patients with chronic coronary syndromes receiving long-term antiplatelet therapy
    Korobkova, V.
    Komarov, A. L.
    Shakhmatova, O. O.
    Dobrovolsky, A. B.
    Novikova, E. S.
    Guskova, E. V.
    Titaeva, E. V.
    Yarovaya, E. B.
    Shuleshova, A. G.
    Panchenko, E. P.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2505 - 2505
  • [49] Durability of Bleeding Protection and Factor IX Activity Levels Are Demonstrated in Individuals with and without Adeno-Associated Virus Serotype 5 Neutralizing Antibodies (Titers <:700) with Comparable Safety in the Phase 3 HOPE-B Clinical Trial of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B
    Pipe, Steven W.
    Leebeek, Frank W. G.
    Recht, Michael
    Key, Nigel S.
    Lattimore, Susan
    Castaman, Giancarlo
    Cooper, David
    Verweij, Stephanie
    Dolmetsch, Ricardo
    Tarrant, Jacqueline
    Li, Yanyan
    Monahan, Paul E.
    Miesbach, Wolfgang A.
    BLOOD, 2022, 140 : 4904 - 4906
  • [50] Prophylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B-LONG study
    Nolan, Beatrice
    Recht, Michael
    Rendo, Pablo
    Falk, Aletta
    Foster, Meredith
    Casiano, Sandra
    Rauch, Antoine
    Shapiro, Amy
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (04) : 485 - 492
12345